Arteris director sells 90,000 shares via trust

Rhea-AI Filing Summary

Arteris, Inc. director Saiyed Atiq Raza, through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, reported open‑market sales of a total of 90,000 shares of Arteris common stock at weighted average prices around $22 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, the trust holds 300,000 shares indirectly, and Raza also holds 20,839 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 90,000 shares

Net Sell 3 txns

Insider RAZA SAIYED ATIQ

Role Director

Sold 90,000 shs ($1.99M)

Type	Security	Shares	Price	Value
Sale	Common Stock	17,060	$22.162	$378K
Sale	Common Stock	72,940	$22.1589	$1.62M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 300,000 shares (Indirect, Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012); Common Stock — 20,839 shares (Direct)

Footnotes (4)

1. F1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025.
2. F2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.46 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.
4. F4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.05 to $22.24 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 90,000 shares Sale price range (first day): $22.00–$22.46 per share Sale price range (second day): $22.05–$22.24 per share +4 more

7 metrics

Shares sold 90,000 shares Total open-market sales reported across two transactions

Sale price range (first day) $22.00–$22.46 per share Price range for weighted average sale noted in footnote F2

Sale price range (second day) $22.05–$22.24 per share Price range for weighted average sale noted in footnote F4

Shares after 4/20 sale (indirect) 300,000 shares Indirect holdings by revocable trust following the 17,060-share sale

Direct holdings 20,839 shares Directly held Arteris common stock as of 2026-04-17

Shares sold 2026-04-17 72,940 shares Open-market sale by revocable trust at $22.1589 weighted average

Shares sold 2026-04-20 17,060 shares Open-market sale by revocable trust at $22.1620 weighted average

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, revocable trust, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan that was adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

revocable trust financial

"The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust..."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Arteris (AIP) director Saiyed Atiq Raza report?

Arteris director Saiyed Atiq Raza reported open‑market sales totaling 90,000 shares of common stock. The trades were executed through a revocable trust associated with him, with weighted average prices around $22 per share, according to the Form 4 filing.

At what prices were the Arteris (AIP) shares sold in this Form 4?

The reported Arteris share sales occurred at weighted average prices around $22 per share. Individual trades on one day ranged from $22.00 to $22.46, and on another day from $22.05 to $22.24, reflecting multiple executions within narrow price bands.

How many Arteris (AIP) shares does the trust hold after the reported sales?

After the reported transactions, the revocable trust associated with director Saiyed Atiq Raza holds 300,000 Arteris common shares indirectly. This figure is disclosed as the number of shares beneficially owned following the most recent open‑market sale recorded in the Form 4 filing.

Does Arteris (AIP) director Saiyed Atiq Raza still own shares directly after these trades?

Yes. Separate from the trust holdings, the Form 4 shows Saiyed Atiq Raza with 20,839 Arteris common shares held directly. This direct position is reported as a holding entry as of the same general period as the disclosed trust‑based sales.

Were the Arteris (AIP) insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were made under a Rule 10b5‑1 trading plan adopted on November 7, 2025. Such pre‑arranged plans schedule trades in advance, providing a structured framework for insider stock transactions.

Who executed the Arteris (AIP) share sales reported in the Form 4?

The sales were executed by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, for which Raza serves as trustee. The filing attributes the transactions to this trust, reflecting indirect beneficial ownership of the sold and remaining shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAZA SAIYED ATIQ

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CALIFORNIA 95008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		S(1)		72,940	D	$22.1589(2)	317,060	I	Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012(3)
Common Stock	04/20/2026		S(1)		17,060	D	$22.162(4)	300,000	I	Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012
Common Stock								20,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.46 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.

4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.05 to $22.24 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for S. Atiq Raza	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)